Comparison of the frequency of loss-of-function LZTR1 variants between schwannomatosis patients and the general population
- PMID: 35391499
- PMCID: PMC9324957
- DOI: 10.1002/humu.24376
Comparison of the frequency of loss-of-function LZTR1 variants between schwannomatosis patients and the general population
Abstract
Schwannomatosis is a rare tumor predisposition syndrome that causes multiple schwannomas. Germline loss-of-function (LoF) LZTR1 variants were only recently identified as disease-causing, so relatively few variants have been identified in patients. In addition, many LoF variants exist in Genome Aggregation Database (gnomAD) in people who do not have clinical symptoms of schwannomatosis. These factors, and the incomplete penetrance seen in this condition, hinder definitive interpretation of the clinical significance of novel LoF variants identified in schwannomatosis patients. We collated published LOF LZTR1 variants identified in schwannomatosis patients and classified them according to current American College of Medical Genetics and Genomics/Association for Molecular Pathology/Association of Clinical Genomic Science guidelines. Subsequently, pathogenic/likely pathogenic schwannomatosis-associated LoF variants were compared with LoF LZTR1 variants reported in gnomAD data. Using current classification guidelines, 64/71 LoF LZTR1 variants reported in schwannomatosis patients in the literature were classified as pathogenic/likely pathogenic, and their frequency in probands 64/359 (17.8%) was significantly higher than the frequency of potential LoF variants identified in the general population (0.36%; p < 0.0001). The majority of published classifications of schwannomatosis-associated LoF variants are robust. However, the high frequency of LoF LZTR1 variants in the general population suggests that LZTR1 variants confer a reduced risk of schwannomas compared to germline NF2 and SMARCB1 pathogenic variants, making classification of novel variants challenging.
Keywords: ACMG; LZTR1; loss-of-function; schwannomatosis; variant classification.
© 2022 The Authors. Human Mutation published by Wiley Periodicals LLC.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
References
-
- Abou Tayoun, A. N. , Pesaran, T. , DiStefano, M. T. , Oza, A. , Rehm, H. L. , Biesecker, L. G. , & Harrison, S. M. , ClinGen Sequence Variant Interpretation Working Group (ClinGen SVI) . (2018). Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterion. Human Mutation, 39(11), 1517–1524. - PMC - PubMed
-
- Biegel, J. A. , Zhou, J. Y. , Rorke, L. B. , Stenstrom, C. , Wainwright, L. M. , & Fogelgren, B. (1999). Germ‐line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Research, 59(1), 74–79. - PubMed
-
- Bigenzahn, J. W. , Collu, G. M. , Kartnig, F. , Pieraks, M. , Vladimer, G. I. , Heinz, L. X. , Sedlyarov, V. , Schischlik, F. , Fauster, A. , Rebsamen, M. , Parapatics, K. , Blomen, V. A. , Müller, A. C. , Winter, G. E. , Kralovics, R. , Brummelkamp, T. R. , Mlodzik, M. , & Superti‐Furga, G. (2018). LZTR1 is a regulator of RAS ubiquitination and signaling. Science, 362(6419), 1171–1177. - PMC - PubMed
-
- Boyd, C. , Smith, M. J. , Kluwe, L. , Balogh, A. , Maccollin, M. , & Plotkin, S. R. (2008). Alterations in the SMARCB1 (INI1) tumor suppressor gene in familial schwannomatosis. Clinical Genetics, 74(4), 358–366. - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous